Korean J Urol.  1994 Dec;35(12):1339-1346.

A Retrospective Study Comparing M-VAC and CISCA Chemotherapy in Advanced Urothelial Transitional Cell Carcinoma

Affiliations
  • 1Department of Urology, College of Medicine, Kosin University, Pusan, Korea.

Abstract

We retrospectively reviewed 57 patients with advanced urothelial transitional cell carcinomas who were treated with methotrexate, vinblastine, doxorubicin and cisplatin(M-VAC) chemotherapy, in 45 patients, and cisplatin, cyclophosphamide and doxorubicin(CISCA) chemotherapy, in 12 patients. The complete response rate of total patients was 14%(8/57 patients) and the partial response rate was 30%(17/57). The response rates according to lesion sites were 56.7%(17/31) in bladder, 50%(1/2) ureter, 50%(4/8) lung, 42%(15/35) lymph node, 25%(1/4) renal pelvis and 25%(3/12) bone. The mean response period was 8.1 months in complete response group and 6.8 months in partial response group. The response rates(in M-VAC/CISCA) according to primary lesion sites were 50%/25% in bladder, 40%/50% in renal pelvis and 0%/50% in ureter and statically significant differences were not noticed in response rates(p>0.05). The response rates in M-VAC and CISCA chemotherapy groups were 47%(21/45), 33%(4/12) but statistically significant differences were not noticed in response rates (p>0.05). The 3-year survival rates were 29% in M-VAC chemotherapy group and 8% in CISCA and the 3-year survival rates of response groups were 57% in M-VAC chemotherapy group and 25% in CISCA, but they were not related statistically(p>0.05). In comparison of drug toxicity, toxic symptoms were seen mostly in M-VAC chemotherapy group and most common symptom was bone marrow suppression. In conclusion, the response & survival rates between M-VAC and CISCA chemotherapy groups were not related statistically(p>0.05), but the response & survival rates of M-VAC chemotherapy group were generally superior than CISCA chemotherapy group.

Keyword

Urothelial transitional cell carcinoma; M-VAC and CISCA chemotherapy

MeSH Terms

Bone Marrow
Carcinoma, Transitional Cell*
Cisplatin
Cyclophosphamide
Doxorubicin
Drug Therapy*
Drug-Related Side Effects and Adverse Reactions
Humans
Kidney Pelvis
Lung
Lymph Nodes
Methotrexate
Retrospective Studies*
Survival Rate
Ureter
Urinary Bladder
Vinblastine
Cisplatin
Cyclophosphamide
Doxorubicin
Methotrexate
Vinblastine
Full Text Links
  • KJU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr